Wolverine Trading
IMVT icon

Wolverine Trading’s Immunovant IMVT Stock Holding History

Wolverine Trading’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,900
Closed -$237K – 5142
2025
Q1 		$237K Sell
12,900
-8,300
-39% -$174K ﹤0.01% 3775
2024
Q4 		$506K Buy
21,200
+10,700
+102% +$304K ﹤0.01% 3381
2024
Q3 		$294K Buy
10,500
+300
+3% +$8.85K ﹤0.01% 3649
2024
Q2 		$269K Buy
10,200
+3,500
+52% +$99.6K ﹤0.01% 3520
2024
Q1 		$216K Buy
+6,700
New +$244K ﹤0.01% 3710
2023
Q4 		– Sell
-33,300
Closed -$1.28M – 4823
2023
Q3 		$1.28M Buy
+33,300
New +$753K ﹤0.01% 1930
2021
Q4 		– Sell
-15,500
Closed -$137K – 6325
2021
Q3 		$137K Sell
15,500
-1,500
-9% -$13.5K ﹤0.01% 5605
2021
Q2 		$184K Buy
+17,000
New +$237K ﹤0.01% 5071

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wolverine Trading's IMVT Position: Q2 2025 in Review

Wolverine Trading sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 11,112 shares — an estimated $168K sold.

Wolverine Trading first reported a position in IMVT in Q3 2024 and held it in 3 quarters. The position peaked at $375K in Q4 2024. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • Wolverine Trading reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 11,112 Immunovant shares in Q2 2025, an estimated $168K.
  • Wolverine Trading first reported a position in Immunovant in Q3 2024 and held it in 3 quarters.
  • Wolverine Trading's Immunovant position peaked at $375K in Q4 2024.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.